These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1045 related articles for article (PubMed ID: 32729335)

  • 1. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
    Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
    J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
    Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N
    Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
    Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
    Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Retrospective Chart Review Evaluating Efficacy, Tolerability, and Cost of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Older Adults.
    Davis LE; Pogge EK
    High Blood Press Cardiovasc Prev; 2020 Aug; 27(4):331-338. PubMed ID: 32651891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NMR-based lipoprotein analysis for patients with severe hypercholesterolemia undergoing lipoprotein apheresis or PCSK9-inhibitor therapy (NAPALI-Study).
    Schettler VJ; Muellendorff F; Schettler E; Platzer C; Norkauer S; Julius U; Neumann CL
    Ther Apher Dial; 2019 Oct; 23(5):467-473. PubMed ID: 30663261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
    Schettler VJJ; Ringel J; Jacob S; Julius U; Klingel R; Heigl F; Roeseler E; Grützmacher P;
    Atheroscler Suppl; 2017 Nov; 30():44-49. PubMed ID: 29096860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
    Arca M
    Atherosclerosis; 2017 Jan; 256():134-145. PubMed ID: 27993383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis.
    Matta A; Bongard V; Bouisset F; Taraszkiewicz D; Rabès JP; Ferrières J
    Med Sci Monit; 2021 May; 27():e928784. PubMed ID: 33958572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience with proprotein convertase subtilisin/kexine type 9 inhibitors (PCSK9i) in patients undergoing lipoprotein apheresis.
    Tselmin S; Julius U; Weinert N; Bornstein SR; Schatz U
    Atheroscler Suppl; 2019 Dec; 40():38-43. PubMed ID: 31818448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies.
    Raal FJ; Hegele RA; Ruzza A; López JAG; Bhatia AK; Wu J; Wang H; Gaudet D; Wiegman A; Wang J; Santos RD
    Arterioscler Thromb Vasc Biol; 2024 May; 44(5):1156-1164. PubMed ID: 38545781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways.
    Cammisotto V; Baratta F; Castellani V; Bartimoccia S; Nocella C; D'Erasmo L; Cocomello N; Barale C; Scicali R; Di Pino A; Piro S; Del Ben M; Arca M; Russo I; Purrello F; Carnevale R; Violi F; Pastori D; Pignatelli P
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281247
    [No Abstract]   [Full Text] [Related]  

  • 12. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perceptions and Barriers on the Use of Proprotein Subtilisin/Kexin Type 9 Inhibitors in Heterozygous Familial Hypercholesterolemia (From a Survey of Primary Care Physicians and Cardiologists).
    Wong ND; Bang M; Block RC; Peterson ALH; Karalis DG
    Am J Cardiol; 2021 Aug; 152():57-62. PubMed ID: 34147211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry.
    Schmidt N; Dressel A; Grammer TB; Gouni-Berthold I; Julius U; Kassner U; Klose G; König C; Koenig W; Otte B; Parhofer KG; Reinhard W; Schatz U; Schunkert H; Steinhagen-Thiessen E; Vogt A; Laufs U; März W
    Atherosclerosis; 2018 Oct; 277():314-322. PubMed ID: 30270065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors.
    Hines DM; Rane P; Patel J; Harrison DJ; Wade RL
    Vasc Health Risk Manag; 2018; 14():409-418. PubMed ID: 30573963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis.
    Kawashiri MA; Nohara A; Higashikata T; Tada H; Nakanishi C; Okada H; Konno T; Sakata K; Hayashi K; Inazu A; Mabuchi H; Yamagishi M
    Atherosclerosis; 2017 Oct; 265():225-230. PubMed ID: 28926730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
    Jetty V; Glueck CJ; Lee K; Goldenberg N; Prince M; Kumar A; Goldenberg M; Anand I; Wang P
    Vasc Health Risk Manag; 2017; 13():247-253. PubMed ID: 28740397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives.
    Catapano AL; Pirillo A; Norata GD
    Vasc Health Risk Manag; 2017; 13():343-351. PubMed ID: 28919772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving trend in the management of heterozygous familial hypercholesterolemia in Italy: A retrospective, single center, observational study.
    D'Erasmo L; Commodari D; Di Costanzo A; Minicocci I; Polito L; Ceci F; Montali A; Maranghi M; Arca M
    Nutr Metab Cardiovasc Dis; 2020 Oct; 30(11):2027-2035. PubMed ID: 32830020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid-lowering therapy with PCSK9-inhibitors in the real-world setting: Two-year experience of a regional lipid clinic.
    Zafrir B; Jubran A
    Cardiovasc Ther; 2018 Oct; 36(5):e12439. PubMed ID: 29863817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.